JPRN-jRCT1080222234已完成Unknown
esina tablets special drug use surveillance: Mild type 2 diabetes mellitus
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 19,192
研究概览
简要总结
This surveillance was conducted to examine the safety and efficacy of long-term Nesina therapy in patients with mild type 2 diabetes mellitus. The surveillance results raised no major concerns about the safety or efficacy of long-term Nesina therapy.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with HbA1c (JDS value) less and equal 7.0% at the time of enrolment (within 3 months before initiation of Nesina therapy), regardless of the use of antidiabetic medication.
排除标准
- •Patients contraindicated for Nesina
- •(1) Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus.
- •(2) Patients with severe infection, pre- or post-operative patients, or patients with serious traumatic injury.
- •(3) Patients with a history of hypersensitivity to any ingredient of Nesina.
研究者
相似试验
已完成
Unknown
Alogliptin tablets special drug use surveillance Type 2 diabetes mellitus: monotherapy/combination therapy with alpha-GIJPRN-jRCT1080222203Takeda Pharmaceutical Company Limited3,317
已完成
不适用
Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With SulfonylureaSurveillanceNCT01964950Takeda1,101
已完成
Unknown
Alogliptin tablets specified drug-use survey Type 2 diabetic patients receiving combination therapy with a hypoglycemic agent (e.g., insulin preparations or rapid-acting insulin secretagogues)Type 2 diabetes mellitusJPRN-jRCT1080222558Takeda Pharmaceutical Company Limited964
已完成
不适用
Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"Type 2 Diabetes MelitusNCT01945242Takeda1,374
已完成
不适用
Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With BiguanidesSurveillanceNCT01964976Takeda1,096